Cells expressing parathyroid hormone 1 receptor and uses thereof

Abstract

Disclosed herein are pluripotent stem cells cultured with one or more peptide and methods of isolating said stem cells. Also disclosed are methods of targeting the stem cells to a desired region or area within an organism. Also disclosed are methods of using the isolated stem cells for the improvement of fertility, for the promotion of hair growth, for the treatment or prevention of skin conditions, for the treatment or improvement of bone disorders, for the treatment of malignancies, and for the treatment of neurological disorders.

1 - 19 . (canceled) 
     
     
         20 . A method for isolating a stem cell population characterized in that it expresses parathyroid hormone type 1 receptor (PTH1R), is 2.5 to 4.5 μm in diameter, forms embryoid-like bodies when cultured, and is capable of differentiation into ectoderm, mesoderm, and endoderm upon culture, the method comprising:
 contacting a sample comprising the stem cell population with an antibody specific for PTH1R, to form an antibody-bound stem cell population; 
 isolating the antibody-bound stem cell population; and 
 releasing the stem cell from the antibody. 
 
     
     
         21 . The method of  claim 20 , further comprising:
 contacting a sample comprising the antibody-bound stem cell population with magnetic beads; and   applying a magnetic field, thereby isolating the antibody-bound stem cell population.   
     
     
         22 . The method of  claim 20 , wherein the sample is obtained from a sample selected from the group consisting of adipose tissue, bone marrow, peripheral blood, seminal fluid, ovarian follicular fluid, and combinations thereof. 
     
     
         23 . The method of  claim 20 , wherein the isolated stem cell population comprises stem cells that are 2.5 μm in diameter and expressive of classical CD markers. 
     
     
         24 . The method of  claim 20 , wherein the isolated stem cell population comprises stem cells that are isolated in quantities of about 10,000, 50,000, 100,000, 500,000, 1,000,000, 5,000,000, or 10,000,000 cells/mL tissue sample, or an amount within a range defined by any two of the aforementioned values. 
     
     
         25 - 26 . (canceled) 
     
     
         27 . The method of  claim 20 , further comprising:
 contacting a sample comprising the stem cell population with anti-CD45 antibody; and   removing cells unbound by anti-CD45 antibody.   
     
     
         28 - 29 . (canceled) 
     
     
         30 . A method of improving fertility in a subject comprising:
 selecting a subject in need of improved fertility; and   administering a therapeutically effective amount of an isolated population of pluripotent stem cells to said subject, wherein the stem cells express parathyroid hormone type 1 receptor (PTH1R), are 2.5 to 4.5 μm in diameter, form embryoid-like bodies when cultured, and are capable of differentiation into ectoderm, mesoderm, and endoderm upon culture.   
     
     
         31 . The method of  claim 30 , wherein the pluripotent stem cells are autologous. 
     
     
         32 . The method of  claim 30 , wherein the therapeutically effective amount is an amount sufficient to cause a detectable improvement in ovarian function, oocyte quality, endometrial thickness, endometrial receptivity, or combinations thereof. 
     
     
         33 . The method of  claim 30 , wherein the therapeutically effective amount of isolated population of pluripotent stem cells is administered by injection into the testicles or uterus. 
     
     
         34 . The method of  claim 30 , wherein the therapeutically effective amount of isolated population of pluripotent stem cells is administered intravenously to the subject into a uterine artery to promote thickening and receptivity of an endometrial wall. 
     
     
         35 . The method of  claim 34 , wherein thickening of the endometrial wall is increased by at least about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or greater. 
     
     
         36 . The method of  claim 30 , wherein the therapeutically effective amount of isolated population of pluripotent stem cells is administered intravenously to the subject into an ovarian artery to increase the number and quality of eggs. 
     
     
         37 . The method of  claim 30 , wherein the pluripotent stem cells are isolated from a sample selected from the group consisting of adipose tissue, bone marrow, peripheral blood, seminal plasma, and ovarian follicular fluid, and/or combinations thereof. 
     
     
         38 - 44 . (canceled) 
     
     
         45 . A method of improving, ameliorating, reversing, or treating a bone disorder comprising administering an effective amount of a composition comprising an isolated population of pluripotent stem cells to a subject in need, wherein the stem cells express parathyroid hormone type 1 receptor (PTH1R), are 2.5 to 4.5 μm in diameter, form embryoid-like bodies when cultured, and are capable of differentiation into ectoderm, mesoderm, and endoderm upon culture. 
     
     
         46 . The method of  claim 45 , wherein the bone disorder is a bone injury. 
     
     
         47 . The method of  claim 46 , wherein the bone injury is a bone fracture. 
     
     
         48 . The method of  claim 47 , wherein the bone fracture is a spinous fracture. 
     
     
         49 . The method of  claim 45 , wherein the bone disorder is osteoporosis. 
     
     
         50 . The method of  claim 45 , wherein the bone disorder is osteopenia. 
     
     
         51 . The method of  claim 45 , wherein the composition is subcutaneously injected to the subject. 
     
     
         52 . The method of  claim 45 , wherein the composition is administered intravenously to the subject. 
     
     
         53 . The method of  claim 45 , wherein the composition is administered intra-arterially to the subject. 
     
     
         54 . The method of  claim 53 , wherein the composition is administered into one or more of the uterine, pancreatic, or ovarian artery. 
     
     
         55 - 82 . (canceled)